


APPROVED	O.G. File	
BY	CLASS	SUBCLASS
DRAFTSMAN		

SASAKI et al Q62621  
 PHARMACEUTICAL COMPOSITION...  
 Filed: January 23, 2001  
 Waddell A. Biggart  
 202-293-7060  
 1 of 6

09/744328

1/6

Fig. 1




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

SASAKI et al Q62621  
PHARMACEUTICAL COMPOSITION...  
Filed: January 23, 2001  
Waddell A. Biggart  
202-293-7060  
2 of 6

U9/744328

2/6

Fig.2




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

SASAKI et al Q62621  
 PHARMACEUTICAL COMPOSITION...  
 Filed: January 23, 2001  
 Waddell A. Biggart  
 202-293-7060  
 3 of 6

09/744328

3/6


Fig.3



- without addition of TGF- $\beta$  and galectin-3
- without addition of TGF- $\beta$ , and with addition of 50  $\mu$ g/ml of galectin-3
- ▼--- with addition of 0.4 ng/ml of TGF- $\beta$ , and without addition of galectin-3
- ▽--- with addition of 0.4 ng/ml of TGF- $\beta$  and 50  $\mu$ g/ml of galectin-3

4/6

Fig. 4




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

SASAKI et al Q62621  
 PHARMACEUTICAL COMPOSITION...  
 Filed: January 23, 2001  
 Waddell A. Biggart  
 202-293-7060  
 5 of 6

U9/744328

5/6

Fig. 5



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

SASAKI et al Q62621  
 PHARMACEUTICAL COMPOSITION...  
 Filed: January 23, 2001  
 Waddell A. Biggart  
 202-293-7060  
 6 of 6

U9/744328

6/6

Fig. 6

